Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence

• Published in: Neuropsychopharmacology (New York, N.Y.) Vol. 42; no. 5; pp. 1049 - 1057
• Main Authors: Murphy, Anna, Nestor, Liam J, McGonigle, John, Paterson, Louise, Boyapati, Venkataramana, Ersche, Karen D, Flechais, Remy, Kuchibatla, Shankar, Metastasio, Antonio, Orban, Csaba, Passetti, Filippo, Reed, Laurence, Smith, Dana, Suckling, John, Taylor, Eleanor, Robbins, Trevor W, Lingford-Hughes, Anne, Nutt, David J, Deakin, John Fw, Elliott, Rebecca
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.04.2017
• Subjects: Abstinence; Addictions; Adult; Alcohol; Alcoholism - physiopathology; Alcoholism - psychology; Anticipation, Psychological; Azabicyclo Compounds - administration & dosage; Brain - drug effects; Brain - physiopathology; Brain Mapping; Cocaine; Dopamine; Double-Blind Method; Drug use; Female; Humans; Impulsivity; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Middle Aged; Monetary incentives; Narcotics; Neural networks; Neurobiology; Original; Oxazoles - administration & dosage; Psychiatry; Receptors, Dopamine D3 - antagonists & inhibitors; Reward; Substance-Related Disorders - physiopathology; Substance-Related Disorders - psychology; Young Adult; United Kingdom > UK
• ISSN: 0893-133X; 1740-634X
• DOI: 10.1038/npp.2016.289

Evidence suggests that disturbances in neurobiological mechanisms of reward and inhibitory control maintain addiction and provoke relapse during abstinence. Abnormalities within the dopamine system may contribute to these disturbances and pharmacologically targeting the D3 dopamine receptor (DRD3) is therefore of significant clinical interest. We used functional magnetic resonance imaging to investigate the acute effects of the DRD3 antagonist GSK598809 on anticipatory reward processing, using the monetary incentive delay task (MIDT), and response inhibition using the Go/No-Go task (GNGT). A double-blind, placebo-controlled, crossover design approach was used in abstinent alcohol dependent, abstinent poly-drug dependent and healthy control volunteers. For the MIDT, there was evidence of blunted ventral striatal response to reward in the poly-drug-dependent group under placebo. GSK598809 normalized ventral striatal reward response and enhanced response in the DRD3-rich regions of the ventral pallidum and substantia nigra. Exploratory investigations suggested that the effects of GSK598809 were mainly driven by those with primary dependence on alcohol but not on opiates. Taken together, these findings suggest that GSK598809 may remediate reward deficits in substance dependence. For the GNGT, enhanced response in the inferior frontal cortex of the poly-drug group was found. However, there were no effects of GSK598809 on the neural network underlying response inhibition nor were there any behavioral drug effects on response inhibition. GSK598809 modulated the neural network underlying reward anticipation but not response inhibition, suggesting that DRD3 antagonists may restore reward deficits in addiction.